Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
By E. Olsen, Youn H. Kim, T. Kuzel, T. Pacheco, F. Foss, S. Parker, S. Frankel, Cong Chen, J. Ricker, J. Arduino and 1 more. Journal of Clinical Oncology, 2007
974 citations recorded by the source corpus.
Subfields: Dermatology, Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/cb36c8a1f79c5580282fa9183ab71f10aca958c1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. (2009, background): “The activity of romidepsin in cutaneous T-cell lymphoma (CTCL) seems to be a class effect, with other HDIs also found to demonstrate activity.(12,13) Between 2,000 and 3,000 new cases of CTCL occur in the United States each year, with mycosis fungoides (MF) and the Sézary syndrome (SS) being the pre”
- A decade of exploring the cancer epigenome — biological and translational implications (2011, background): “A milestone in therapy using agents that modify the epigenome is the recent FDA approval of vorinostat (Zolinza; Merck) and romidepsin (Istodax; Celgene) for their remarkable efficacy in cutaneous T cell lymphom”
- Histone Deacetylase Inhibitors as Anticancer Drugs (2017, background): “Administration of SAHA in refractory CTCL patients showed in phase II trials objective response in nearly 30% [166,167].”
- Cancer epigenetics: from mechanism to therapy. (2012, background): “Based on impressive preclinical and clinical data, two pan-HDAC inhibitors, Vorinostat and Romidepsin, have recently been granted FDA approval (Olsen et al., 2007; Piekarz et al., 2009) for clinical use in patients with cutaneous T cell lymphoma (Figure 1).”